Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations

Am J Otolaryngol. 2021 May-Jun;42(3):102934. doi: 10.1016/j.amjoto.2021.102934. Epub 2021 Jan 27.

Abstract

Spindle cell larynx carcinoma (SpCC) represents around 3% of laryngeal cancers. It is originated by a single cancer stem cell undergoing epithelial to mesenchymal transition. This explains the aggressiveness, the peculiar resistance to conventional therapy and the frequent relapses. We focused on this particular cancer subset characteristics in patients, in early and advanced stages primarily aiming to define and highlight the differences with Laryngeal Squamous Cell Carcinoma (LSCC) focusing on clinical features, treatments, follow-up and survival in a patient's cohort composed by comparable cases from two subgroups.

Keywords: Larynx; Spidle cell carcinoma; Squamous cell carcinoma; Statistical analysis; Survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / pathology*
  • Laryngeal Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Sarcoma / mortality
  • Sarcoma / pathology*
  • Sarcoma / therapy
  • Survival Rate

Substances

  • Antineoplastic Agents